First in Human Study of M1069 in Advanced Solid Tumors

NCT05198349 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Overarching portfolio-level review of the company's oncology pipeline resulted in early termination of the study. The study was not terminated due to safety.

Conditions

Metastatic or Locally Advanced Unresectable Solid Tumors

Interventions

DRUG: M1069

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]